Literature DB >> 12453216

Ribosomal and non-ribosomal resistance to oxazolidinones: species-specific idiosyncrasy of ribosomal alterations.

P Sander1, L Belova, Y G Kidan, P Pfister, A S Mankin, E C Böttger.   

Abstract

A derivative of Mycobacterium smegmatis, which carries only one functional rRNA (rrn) operon, was used to isolate mutants resistant to the ribosome-targeted antibiotic linezolid. Isolation and characterization of linezolid-resistant clones revealed two classes of mutants. Ribosomes from class I mutants are resistant to oxazolidinones in an in vitro peptidyl transferase assay, indicating that resistance maps to the ribosome component. In contrast, ribosomes from class II mutants show wild-type susceptibility to a linezolid derivative in vitro, pointing to a non-ribosomal mechanism of resistance. Introduction of a wild-type ribosomal RNA operon into linezolid-resistant strains restored linezolid sensitivity in class I mutants, indicating that resistance (i) maps to the rRNA and (ii) is recessive. Sequencing of the entire rrn operon identified a single nucleotide alteration in 23S rRNA of class I mutant strains, 2447G --> T (Escherichia coli numbering). Introduction of mutant rrl2447T into M. smegmatis rrn- resulted in a linezolid-resistant phenotype, demonstrating a cause-effect relationship of the 2447G --> T alteration. The 2447G --> T mutation, which renders M. smegmatis linezolid resistant, confers lethality in E. coli. This finding is strong evidence of structural and pos-sibly functional differences between the ribosomes of Gram-positive and Gram-negative bacteria. In agreement with the results of the in vitro assay, class II mutants show a wild-type sequence of the complete rRNA operon. The lack of cross-resistance of the class II mutants to other antibiotics suggests a resistance mechanism other than activation of a broad-spectrum multidrug transporter.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12453216     DOI: 10.1046/j.1365-2958.2002.03242.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  30 in total

Review 1.  Resistance to linezolid caused by modifications at its binding site on the ribosome.

Authors:  Katherine S Long; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

Review 2.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

3.  Evaluation of the cell growth of mycobacteria using Mycobacterium smegmatis mc2 155 as a representative species.

Authors:  Jorge A Gonzalez-Y-Merchand; Ruben Zaragoza-Contreras; Rosalina Guadarrama-Medina; Addy C Helguera-Repetto; Sandra Rivera-Gutierrez; Jorge F Cerna-Cortes; Leopoldo Santos-Argumedo; Robert A Cox
Journal:  J Microbiol       Date:  2012-06-30       Impact factor: 3.422

4.  Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.

Authors:  Katherine S Long; Christian Munck; Theis M B Andersen; Maria A Schaub; Sven N Hobbie; Erik C Böttger; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

5.  Molecular detection of linezolid resistance in Enterococcus faecium and Enterococcus faecalis by use of 5' nuclease real-time PCR compared to a modified classical approach.

Authors:  Guido Werner; Birgit Strommenger; Ingo Klare; Wolfgang Witte
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

6.  In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants.

Authors:  Doris Hillemann; Sabine Rüsch-Gerdes; Elvira Richter
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

7.  Structural basis for cross-resistance to ribosomal PTC antibiotics.

Authors:  Chen Davidovich; Anat Bashan; Ada Yonath
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-19       Impact factor: 11.205

8.  Tools for characterizing bacterial protein synthesis inhibitors.

Authors:  Cédric Orelle; Skylar Carlson; Bindiya Kaushal; Mashal M Almutairi; Haipeng Liu; Anna Ochabowicz; Selwyn Quan; Van Cuong Pham; Catherine L Squires; Brian T Murphy; Alexander S Mankin
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

9.  The emergence of linezolid resistance among Enterococci in intestinal microbiota of treated patients is unrelated to individual pharmacokinetic characteristics.

Authors:  N Bourgeois-Nicolaos; T T Nguyen; G Defrance; L Massias; L Alavoine; A Lefort; V Noel; E Senneville; F Doucet-Populaire; F Mentré; A Andremont; X Duval
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

10.  Linezolid for treatment of chronic extensively drug-resistant tuberculosis.

Authors:  Myungsun Lee; Jongseok Lee; Matthew W Carroll; Hongjo Choi; Seonyeong Min; Taeksun Song; Laura E Via; Lisa C Goldfeder; Eunhwa Kang; Boyoung Jin; Hyeeun Park; Hyunkyung Kwak; Hyunchul Kim; Han-Seung Jeon; Ina Jeong; Joon Sung Joh; Ray Y Chen; Kenneth N Olivier; Pamela A Shaw; Dean Follmann; Sun Dae Song; Jong-Koo Lee; Dukhyoung Lee; Cheon Tae Kim; Veronique Dartois; Seung-Kyu Park; Sang-Nae Cho; Clifton E Barry
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.